(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 24.2MM | +8% |
Operating Income | -41.3MM | -6% |
Operating Expenses | 65.5MM | - |
Net Income | -41.6MM | -6% |
R&D | 29.9MM | -11% |
G&A | 32.4MM | +6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to purc
Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) is possibly approaching a major achievement in its business, so we would...
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it has signed an investment agreement with current shareholders, led by Perceptive Advisors LLC and its Discovery Fund and a life-scienc
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies -- BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have bee
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), has sold 18,235 shares of the company on March 21, 2024, according to a recent SEC Filing.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent SEC filing.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent SEC filing.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent SEC filing.
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two upcoming investor conferences. David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Barclays 26th Annual Global Healthcare Conference on Thursday, Marc